Prolastin-C Liquid
Payments companies reported to CMS as associated with Prolastin-C Liquid. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Prolastin-C Liquid, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Prolastin-C Liquid
These are the largest totals companies reported as associated with Prolastin-C Liquid. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| David Mares | Anderson, IN | Pulmonary Disease | $85,796.83 |
| Douglas Hogarth | Chicago, IL | Pulmonary Disease | $78,532.01 |
| Michael Czarnecki | Chattanooga, TN | Pulmonary Disease | $69,997.10 |
| Lewis Kline | Pittsburgh, PA | Pulmonary Disease | $51,271.70 |
| Rajat Walia | Phoenix, AZ | Pulmonary Disease | $51,026.56 |
| Shripal Shrishrimal | Butler, PA | Pulmonary Disease | $46,773.64 |
| Igor Barjaktarevic | Los Angeles, CA | Pulmonary Disease | $44,088.63 |
| Firas Koura | Georgetown, KY | Pulmonary Disease | $39,379.75 |
| Michael Zlupko | Altoona, PA | Pulmonary Disease | $25,330.20 |
| Nashat Rabadi | Buffalo, NY | Pulmonary Disease | $23,177.70 |
Prescribed Prolastin-C Liquid?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.